{"prompt": "['Date and version No: FUTUREGB_Protocol_V6.0_19Jan2022.docr', '10.11. Definition of End of Study', 'The end of study is the point at which all the study data have been entered, any queries resolved, and a', 'hard data lock has taken place of stage 2.', '11. SAFETY REPORTING', \"The trial will be run in accordance with OCTRU's Standard Operating Procedures (SOPs) and operational\", 'policies, which all adhere to applicable UK regulatory requirements. An independent Data and Safety', 'Monitoring Committee (DSMC) and Trial Steering Committee (TSC) will be appointed. The DSMC will', 'monitor data arising from the trial, review confidential interim reports of accumulating data, and', 'recommend whether there are any ethical or safety reasons why the trial should not continue. The TSC', \"will monitor the trial's progress and will provide independent advice. Both committees will comprise\", 'independent clinicians, statisticians, health service researchers and patient representatives. The project', 'will also be monitored by the Sponsor (University of Oxford), and progress reports will be submitted to', 'the Funder. Given the nature of the primary outcome and the interest in key secondary outcomes', '(namely, os and PFS), no formal interim analyses are planned.', '11.1. Definitions', '11.1.1. Adverse Event (AE)', 'An adverse event is any untoward medical occurrence in a clinical trial participant.', 'Note: An adverse event can therefore be any unfavourable and unintended sign (including an abnormal', 'laboratory finding, for example), symptom or disease temporarily associated with the trial procedures,', 'whether or not considered related to the procedures.', '11.1.2. Serious Adverse Event (SAE)', 'A serious adverse event is any untoward medical occurrence that:', 'results in death', 'is life-threatening', 'requires inpatient hospitalisation or prolongation of existing hospitalisation', 'results in persistent or significant disability/incapacity', \"Other important medical events' may also be considered a serious adverse event when, based upon\", 'appropriate medical judgment, the event may jeopardise the participant and may require medical or', 'surgical intervention to prevent one of the outcomes listed above.', 'Note: The term \"life-threatening\" in the definition of \"serious\" refers to an event in which the participant', 'was at risk of death at the time of the event; it does not refer to an event which hypothetically might', 'have caused death if it were more severe.', '11.2. Reporting Procedures', 'It is important to consider the natural history of a high-grade brain tumour affecting each participant', 'enrolled, the expected sequelae of the illness, and the relevance of these complications to the trial', 'Clinical Research Protocol Template version 14.0', 'Page 38 of 65', 'C Copyright: The University of Oxford and Oxford University Hospitals NHS Foundation Trust 2018', 'CONFIDENTIAL']['Date and version No: FUTUREGB_Protocol_V6.0_19Jan2022.doc:', 'treatment. All eligible participants have a poor prognosis, and due to the complexity of their condition', 'are at increased risk of experiencing multiple adverse events. Consequently, only Serious Adverse Events', '(SAE) will be recorded in this trial. This is limited to serious adverse events, which might reasonably', 'occur as a consequence of the trial treatment (i.e. not events that are part of the natural history of the', 'primary disease process or expected complications of a brain tumour).', 'SAEs, as defined above, experienced by a participant from their enrolment until their completion of the', \"trial must be reported in the participant's medical notes, on the trial CRF, and reported to the CTU using\", 'the SAE Reporting Form, within 24 hours of observing or learning of the SAE(s). All sections of the SAE', 'Reporting Form must be completed.', 'A SAE occurring to a participant will be reported to the REC that gave a favourable opinion of the study', \"where in the opinion of the Chief Investigator the event was 'related' (resulted from administration of\", 'any of the research procedures) and \"unexpected\\' in relation to those procedures. Reports of related and', 'unexpected SAEs should be submitted within 15 working days of the Chief Investigator becoming aware', 'of the event, using the HRA report of serious adverse event form', '11.2.1. Events exempt from being reported as SAEs', 'The following hospitalisations are not considered a SAE:', 'a', 'visit to the emergency room or other hospital department < 24 hours, that does not result in', 'admission (unless considered an important medical or life-threatening event)', 'admissions as per protocol for a planned medical/surgical procedure', 'admissions for planned chemotherapy and/or radiotherapy and any related sequelae', 'routine health assessment requiring admission for baseline/trending of health status (e.g.', 'routine colonoscopy)', 'medical/surgical admission other than to remedy ill health and planned prior to entry into the', 'study', 'admission encountered for another life circumstance that carries no bearing on health status and', 'requires no medical/surgical intervention (e.g., lack of housing, economic inadequacy, caregiver', 'respite, family circumstances, administrative reason)', 'admission for administration of anticancer therapy in the absence of any other SAEs (applies to', 'oncology protocols)', 'disease progression where not considered to be related to study intervention', 'non-surgical sequelae which can result from any operative procedure or a diagnosis of', 'malignancy (for example, but not limited to: pneumonia, urinary tract infection, pulmonary', 'embolism, deep vein thrombosis)', 'unplanned admissions resulting from pre-existing co-morbidities recorded at baseline', '11.3. Death during the study', 'Clinical Research Protocol Template version 14.0', 'Page 39 of 65', 'C Copyright: The University of Oxford and Oxford University Hospitals NHS Foundation Trust 2018', 'CONFIDENTIAL']\n\n###\n\n", "completion": "END"}